All information is correct at time of printing and is subject to change without notice. The Devon Formulary and Referral Website is not in any way liable for the accuracy of any information printed and stored by users. For the most up-to-date information, please refer to the website.
February 2025: Tirzepatide for weight management
News
February 2025: Tirzepatide for weight management
NICE TA1026: Tirzepatide solution for injection pre-filled disposable devices have been added to the Devon Formulary section ‘4.5 Drugs used in the treatment of obesity’ as a red option for use in the specialist weight management services for the purposes of weight management in line with NICE TA1026.
Implementation of TA1026 is determined by NICE and NHS England (see here). The national plan for the future is for a phased delivery to patient cohorts in other settings, including primary care-based services, based on NHS England prioritisation criteria.
Until further communication, use of tirzepatide for weight management purposes remains with the specialist weight management service. The formulary entry and traffic light classification for tirzepatide for weight management will be reviewed in the future when more information is available.
See here for the formulary entry for tirzepatide for weight management.
Note: Tirzepatide remains blue (second line) for use in type 2 diabetes in line with NICE TA924.
- See here for the tirzepatide formulary entry for type 2 diabetes and formulary guidance for type 2 diabetes.
